• Eupraxia released first EoE Histology Scoring System sub-score readout from ongoing Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis; results were presented this week at Digestive Disease Week in Chicago.
• Sub-scores tracking inflammation showed broad improvement across reported cohorts at 12 weeks and 36 weeks, supporting earlier signals from symptom and endoscopic assessments.
• Measures linked to tissue architecture and fibrosis also improved in most cohorts at both timepoints, with strongest response at highest dose tested.
• Phase 2b RESOLVE study remains in recruitment at 120 mg and 160 mg doses, with top-line data expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-003051), on May 06, 2026, and is solely responsible for the information contained therein.